Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 July 2023 | Story André Damons | Photo Supplied
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), with his certificate after winning the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

A research paper by a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS) has won the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

The abstract, by Dr Osayande Evbuomwan, was about evaluating the efficacy of a new nuclear medicine radiopharmaceutical in the identification of active disease in patients with rheumatoid arthritis. It was selected for this award by a special committee at the recently concluded SNMMI 2023 Annual Meeting, which took place between 24 and 27 June in Chicago, USA.

Dr Evbuomwan received the award at the Annual Meeting on 26 June.

“It is a good feeling, and I am proud of the UFS Department of Nuclear Medicine for pulling this off. It is another example that hard work pays,” he says.

Comparing this radiopharmaceutical to ultrasound

Dr Evbuomwan says the research that generated the award-winning abstract was aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. The study concluded that this particular radiopharmaceutical (Tc – 99m glucosamine) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints), and is capable of offering prognostic information in patients with rheumatoid arthritis.

This is the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says. He is currently working on comparisons of this radiopharmaceutical to ultrasound and clinical evaluation in the identification of active disease in patients with rheumatoid arthritis. He says there is also ongoing collaboration with the Rheumatology Division of the Internal Medicine Department, which has played a huge role in making this project fruitful.

“This award is an opportunity to put the department and university on the map, with world stage recognition. We believe that as the Nuclear Medicine Department continues to grow in human resources and equipment, the research output will also increase.”

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the whole department is very proud of Dr Evbuomwan’s accomplishments. “What makes his award even more remarkable is that he outperformed candidates from much larger, highly funded institutions,” he says.

This department announced last year the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

News Archive

UFS Camerata ends concert season on a high note
2017-11-02

Description: UFS Camerata  Tags: UFS Camerata  

The final concert at Endler Hall at Stellenbosch University, presented by the
Endler Concert Series, was attended by the UFS Rector and Vice-Chancellor,
Prof Francis Petersen and Mrs Cheslyn Petersen. Here, on stage, is Prof Petersen
with the Camerata.
Photo: Supplied

The OSM Camerata (OSMC) of the Odeion School of Music at the University of the Free State ended the 2017 concert season on a high note with two gala concerts presented in the Western Cape as part of the ensemble’s fifth birthday celebrations. The first concert took place at the well-known Hugo Lambrechts Auditorium in Parow on 20 October 2017. A Stellenbosch University audience also had the privilege of listening to the Camerata at Endler Hall the following day.

A substantial part of the concert programme recited during the concerts was dedicated to prolific South African composer, Prof Hendrik Hofmeyr, in honour of his 60th birthday on 20 November 2017. The ensemble recited Super Flumina Babylonis, Notturno Elegiaco & Spokewals/Phantom Waltz - all works commissioned from Prof Hofmeyr for the OSMC.

The Odeion School of Music awarded the Order of the OSM to Prof Hofmeyr during the concert in gratitude for his tremendous contribution as a South African composer.

The final concert at Endler Hall, presented by the Endler Concert Series, was attended by the UFS Rector and Vice-Chancellor, Prof Francis Petersen, and Mrs Cheslyn Petersen.

According to Marius Coetzee from the Odeion School of Music, the OSMC was strategically founded in 2012 as the OSM’s flagship chamber orchestra with its main objective being to create a catalyst for excellence. From a pedagogical perspective, the OSMC serves as an incubator to nurture fully rounded musicians who are thoroughly prepared for the demands of their trade as orchestral musicians, soloists and conductors. 

Responding to the demand for excellence, on 1 September 2017 it was announced that the OSMC received first prize for the 2017 Ictus International Music Competition (US) as the winner of the category for Conservatory and University Orchestras.

Louis van der Watt, head of strings at the University of Stellenbosch Conservatory and vice conductor of the university’s symphony orchestra, remarked that the OSMC presented an excellent concert. Audience members concurred, saying the OSM Camerata was setting new standards for orchestral playing in South Africa.

Review from Louis van der Watt, University of Stellenbosch (available in Afrikaans)

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept